I agree Our site saves small pieces of text information (cookies) on your device in order to deliver better content and for statistical purposes. You can disable the usage of cookies by changing the settings of your browser. By browsing our website without changing the browser settings you grant us permission to store that information on your device.
Clotrimazole is an imidazole derivative and an antifungal compound and a CYP (cytochrome P450) inhibitor. Clotrimazole has been shown to block the intermediate-conductance, IK1 channels (Ca2+ activated K+ channels), in cells such as erythrocytes. In vitro studies of various yeast strains have demonstrated susceptibility to clotrimazole. Clotrimazole is an activator of MB67 and an inhibitor of CYP3A4 and CYP51A1.
E.B Souto.; b, S.A Wissing.; C.M Barbosa.; R.H Müller. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery.Int. J. Pharm. 2004, 278 (1),71-77 .
Jack D. Sobel.; Doris Brooker.; Gary E. Stein.; Jessica L. Thomason.; Daniel P. Wermeling.; Blake Bradley.; Louis Weinstein. Single oral dose fluconazole compared with conventional clotrimazole topical therapy of Candida vaginitis.American Journal of Obstetrics and Gynecology. 1995, 172 (4),1263-1268 .
Hazard Statements: H302-H315-H319
Harmful if swallowed. Causes skin irritation. Causes serious eye irritation.
Precautionary Statements: P280a-P305+P351+P338-P301+P312a-P321-P332+P313-P501a
Wear protective gloves and eye/face protection. IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. IF SWALLOWED: Specific treatment (see label). If skin irritation occurs: Get medical advice/attention. Dispose of contents/container in accordance with local/regional/national/international regulations.